Navigation Links
Pepscan Therapeutics Strengthens Management Team
Date:1/27/2010

LELYSTAD, The Netherlands, January 27 /PRNewswire/ -- Pepscan Therapeutics, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today named Peter Timmerman, PhD as Chief Technology Officer and Klaus Schwamborn, PhD as Chief Development Officer. These new positions were created after the retirement of its CSO and one of the company founders, Prof. Dr. Rob Meloen.

"Pepscan has recently refocused its R&D program on the application of its proprietary CLIPSTM protein mimicry technology for the generation of monoclonal antibodies and therapeutic peptides"' said Wim Mol, CEO of the company. "This new focus requires a strengthened presence of both technology and biological development in the management team."

Peter Timmerman is inventor of the CLIPSTM technology and as Head of Chemistry drove the advances in protein mimicking for therapeutic antibodies and peptides at Pepscan. He also holds a chair as Professor in Protein Mimetic Chemistry at the University of Amsterdam (UvA). Timmerman studied in Amsterdam, and obtained his PhD summa cum laude from the University of Twente. In 1995, he was recipient of the Backer prize for the best thesis in Organic Chemistry. Before joining Pepscan he did research at the ETH in Zurich, and was Assistant Professor in Supramolecular Chemistry and Technology at the University of Twente. He is co-author of over 80 scientific articles.

Klaus Schwamborn oversees the entire biology required for the pre-clinical development of therapeutic antibodies and peptides. Before joining Pepscan, he was with Celgene, San Diego USA, in target discovery and developed assays for small molecules in the field of cancer and inflammation. Schwamborn holds a PhD in molecular biology from the University of Gottingen, Germany and completed postdoctoral studies at the Institute Pasteur in Paris, France where he mainly focused on cell signaling and post-translational protein modification. He published in high-impact journals and has in total over 15 year hands-on experience in molecular and cellular biology.

"We are very pleased that Peter Timmerman and Klaus Schwamborn join the management team of Pepscan as successors to Rob Meloen. We thank Rob for the invaluable contributions he made to the development of Pepscan. Without his scientific ingenuity Pepscan would not have been where it is today. We are very pleased that Rob will continue to provide support to Pepscan as a scientific adviser", Mol said.

Notes to the editor:

About Pepscan

Pepscan Holding NV is a privately owned company based in Lelystad, the Netherlands. The company focuses on protein mimicking technology for the generation of immune therapeutics. It has developed a pipeline of therapeutic vaccine and antibody programs, of which the most advanced is in Phase II clinical testing. Pepscans proprietary CLIPSTM technology has been proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs. For more information visit http://www.pepscan.com.

About CLIPSTM technology

CLIPSTM (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains and hitherto have been used in antibody and vaccine programs to create superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels, patented proteins).

SOURCE Pepscan Holding N.V.


'/>"/>
SOURCE Pepscan Holding N.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):